Collegium Pharmaceutical Reports Q3 2026 Results, Reaffirms Guidance
Quarterly net revenue reached a record $216.3 million and adjusted EBITDA was $121.6 million. JORNAY PM revenue rose 24% year over year to $51.9 million; AZSTARYS revenue was $26.5 million.
Collegium Pharmaceutical reported its financial results for the quarter ended September 30, 2026, highlighting strong demand across its ADHD portfolio. The company generated record quarterly net revenue of $216.3 million and adjusted EBITDA of $121.6 million. JORNAY PM net revenue reached $51.9 million, a 24% year-over-year increase, while AZSTARYS net revenue was $26.5 million. Management reaffirmed the company's full-year 2026 financial guidance and emphasized a commitment to disciplined capital deployment, including business development and debt reduction.